Stella Pharma Corporation (TYO:4888)
Japan · Delayed Price · Currency is JPY 352.00
-11.00 (-3.03%)
Aug 27, 2026, 1:39 PM JST
Stella Pharma Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 323 | 323 | 961 | 269 | 229 | 100 | |
Revenue Growth | -67.44% | -66.39% | 257.25% | 17.47% | 129.00% | -51.22% |
Cost of Revenue | 44 | 44 | 116 | 52 | 22 | 15 |
Gross Profit | 279 | 279 | 845 | 217 | 207 | 85 |
Selling, General & Admin | 806 | 713 | 590 | 571 | 625 | 555 |
Research & Development | 301 | 301 | 328 | 393 | 374 | 255 |
Operating Expenses | 1,121 | 1,028 | 935 | 977 | 1,013 | 826 |
Operating Income | -842 | -749 | -90 | -760 | -806 | -741 |
Interest Expense | -9 | -7 | -4 | -2 | -2 | -3 |
Interest & Investment Income | - | - | 1 | 1 | 1 | - |
Other Non Operating Income (Expenses) | 1 | -22 | -45 | - | 31 | -20 |
Pretax Income | -850 | -778 | -138 | -761 | -776 | -764 |
Income Tax Expense | 2 | 2 | 2 | 2 | 2 | 3 |
Net Income | -852 | -780 | -140 | -763 | -778 | -767 |
Net Income to Common | -852 | -780 | -140 | -763 | -778 | -767 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 34 | 34 | 33 | 31 | 29 | 28 |
Shares Outstanding (Diluted) | 34 | 34 | 33 | 31 | 29 | 28 |
Shares Change | 0.80% | 1.93% | 7.76% | 7.27% | 2.83% | 40.17% |
EPS (Basic) | -24.87 | -22.93 | -4.19 | -24.63 | -26.94 | -27.31 |
EPS (Diluted) | -24.87 | -22.93 | -4.19 | -24.63 | -26.94 | -27.31 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -345 | 136 | -886 | -853 | -1,127 |
Free Cash Flow Per Share | - | -10.14 | 4.07 | -28.60 | -29.54 | -40.13 |
Gross Margin | 86.38% | 86.38% | 87.93% | 80.67% | 90.39% | 85.00% |
Operating Margin | -260.68% | -231.89% | -9.37% | -282.53% | -351.96% | -741.00% |
Profit Margin | -263.78% | -241.49% | -14.57% | -283.64% | -339.74% | -767.00% |
Free Cash Flow Margin | - | -106.81% | 14.15% | -329.37% | -372.49% | -1127.00% |
EBITDA | -815.5 | -721 | -56 | -725 | -771 | -707 |
EBITDA Margin | -252.48% | -223.22% | -5.83% | -269.52% | - | - |
D&A For EBITDA | 26.5 | 28 | 34 | 35 | 35 | 34 |
EBIT | -842 | -749 | -90 | -760 | -806 | -741 |
EBIT Margin | -260.68% | -231.89% | -9.37% | -282.53% | - | - |